BioArbitrage Intern

Harrison Hayes, a life science advisory and consulting firm with deep roots in research and ideation is seeking a dynamic, entrepreneurial intern for a new spin-out company.

The spin-out, BioArbitrage, LLC, is a start-up biotech with a novel transactional business model that has been validated over the last five years by the success of two funds which have delivered a 39.2% and 47.4% IRR. We have closed 35 of the 36 optioned life science assets we acquired over the life of both funds.

In lieu of launching a third fund, we have determined that our successful model can be optimized by creating a company focused on these unique transactions in the rare and ultra-rare disease space.

The successful candidate will take the helm and sourcing deal flow from non-performing assets at biopharma companies and sourcing technology transfer out-licensing potentials.

Here is how the BioArbitrage model works:

We target life science assets which we can option from academia, technology transfer offices, biotech companies and big pharma.

A valuation is agreed upon by both BioArbitrage and the IP/Technology Owners divesting the Asset. We conduct an exhaustive due diligence analysis utilizing our PIPV proprietary analysis tool to determine that the value sought by the owners of the asset is less than existing market value. An option is exercised by BioArbitrage to purchase the asset for a fixed price within a specified time window (typically 12-18 months).

BioArbitrage then markets the asset to create a controlled auction scenario with interested buyers who are willing to pay more than the strike price agreed upon between the Owners and BioArbitrage. The fund pays the Owners the agreed upon strike price and retains the differential which exceeds the strike price.

The BioArbitrage model generates short term cash flow transacting the deals, and will be also looking to spin off separate companies as an accelerator business model would do.

Through Harrison Hayes' contacts and database of IP opportunities (Transforium Database), BioArbitrage has exposure to global technologies which are "off the grid." By identifying investments that are not "shopped' and being driven up by multiple investors, we are able to make selective decisions at reasonable valuations.

Please forward your resume as this is an immediate position.  Email resumes to wsmith@bioarbitrage.com